Evangelos Tsioupros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Evangelos Tsioupros has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Barry James Campbell
Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 3GE, UK
1 shared publication - Chrysoula Mikra
Laboratory of Organic Chemistry, Faculty of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication - Eleni Kougioumtzian
Department of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece
1 shared publication - Konstantina C. Fylaktakidou
Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece
1 shared publication - Konstantinos Michail
Department of Biochemistry and Biotechnology, University of Thessaly, 41500 Larissa, Greece
1 shared publication - Stamatia Papoutsopoulou
Department of Biochemistry and Biotechnology, Faculty of Life Sciences, University of Thessaly, 41500 Larisa, Greece
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6431
Novel 3-Amino-2-methylquinazolinone NF-κB Inhibitors: Synthesis and Potential Anti-Inflammatory Function
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the 5o (3-amino-6-hydroxy-2-methylquinazolin-4(3H)-one) and 10 (N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-nitrobenzamide). Only the 5o though, bearing OH at R1 (6 position), attenuated the production of pro-inflammatory interleukin 6 in lipopolysaccharide-stimulated human primary macrophage cultures. Molecular docking analysis provides supportive computational evidence that 5o could interact with the p65/DNA complex and therefore could potentially be developed for further studies that aim to inhibit the canonical NF-κB pathway.
- 20 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6431
Open AccessNovel 3-Amino-2-methylquinazolinone NF-κB Inhibitors: Synthesis and Potential Anti-Inflammatory Function
The canonical NF-κB pathway is a major regulator of inflammatory responses, and its persistent activation has been linked to chronic inflammatory diseases and cancer development. It is therefore important to develop effective NF-κB inhibitors that can potentially be utilized in further preclinical studies. In this study, we have synthesized various quinazolinone compounds using novel methodologies. We specifically utilized a two-step protocol comparing an established protocol to a modified alternative procedure and then successfully established a novel one-pot multi-component reaction. All quinazolinones were tested based on their capacity to inhibit tumor necrosis factor-induced NF-κB activation using a commercial transgenic HeLa reporter cell-line. Among the eighteen molecules tested, two compounds affected the NF-κB-dependent luciferase activity, the 5o (3-amino-6-hydroxy-2-methylquinazolin-4(3H)-one) and 10 (N-(6-bromo-2-methyl-4-oxoquinazolin-3(4H)-yl)-4-nitrobenzamide). Only the 5o though, bearing OH at R1 (6 position), attenuated the production of pro-inflammatory interleukin 6 in lipopolysaccharide-stimulated human primary macrophage cultures. Molecular docking analysis provides supportive computational evidence that 5o could interact with the p65/DNA complex and therefore could potentially be developed for further studies that aim to inhibit the canonical NF-κB pathway.